Accueil>>H-p-Chloro-Phe-D-Cys-β-(3-pyridyl)-Ala-D-Trp-Lys-tBu-Gly-Cys-2-Nal-NH₂

H-p-Chloro-Phe-D-Cys-β-(3-pyridyl)-Ala-D-Trp-Lys-tBu-Gly-Cys-2-Nal-NH₂

Catalog No.GA22776

PRL2915, Cpa-D-Cys-Pal-D-Trp-Lys-Tle-Cys-Nal-amide, highly potent human somatostatin subtype 2 receptor (hsst2) antagonist with a Ki of 12 nM. Ki values for the other subtypes were >1000 nM for hsst1, 100 ± 57 nM for hsst3, 895 nM for hsst4, and 520 nM for hsst5, respectively. No agonist activity was found when tested alone at concentrations up to 10 µM. In a rat pituitary growth hormone in vitro antagonist assay versus somatostatin-14 (1nM) the somatostatin octapeptide analog PRL2915 exhibited an IC?? value of 1.8 nM.

Products are for research use only. Not for human use. We do not sell to patients.

H-p-Chloro-Phe-D-Cys-β-(3-pyridyl)-Ala-D-Trp-Lys-tBu-Gly-Cys-2-Nal-NH₂ Chemical Structure

Cas No.: 209006-18-8

Taille Prix Stock Qté
0.5mg
186,00 $US
En stock
1mg
316,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PRL2915, Cpa-D-Cys-Pal-D-Trp-Lys-Tle-Cys-Nal-amide, highly potent human somatostatin subtype 2 receptor (hsst2) antagonist with a Ki of 12 nM. Ki values for the other subtypes were >1000 nM for hsst1, 100 ± 57 nM for hsst3, 895 nM for hsst4, and 5

Avis

Review for H-p-Chloro-Phe-D-Cys-β-(3-pyridyl)-Ala-D-Trp-Lys-tBu-Gly-Cys-2-Nal-NH₂

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for H-p-Chloro-Phe-D-Cys-β-(3-pyridyl)-Ala-D-Trp-Lys-tBu-Gly-Cys-2-Nal-NH₂

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.